August 11, 2020 -- SAB Biotherapeutics has started a phase I trial evaluating SAB-185 for the treatment of COVID-19.
SAB-185 is a human polyclonal antibody therapeutic that may have the potential to treat ill patients and provide antibodies that protect populations against COVID-19. Preclinical data has shown that SAB-185 can neutralize mutated strains of viruses successfully, according to the company.
This is a randomized, double-blind, single and multiple ascending dose study of SAB-185 that involves 28 healthy participants. SAB-185 is targeted to SARS-CoV-2 and aims to work synergistically with a patient's own immune system to both neutralize the virus and activate other immune system components.
The U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense on behalf of the Office of the Assistant Secretary of Defense for Health Affairs and the Defense Health Agency has provided direct support for phase I and phase Ib trials of SAB-185.
Copyright © 2020 scienceboard.net